BioCentury
ARTICLE | Targets & Mechanisms

Neo enough in glioma

July 31, 2014 7:00 AM UTC

A mutation in isocitrate dehydrogenase 1 commonly found in gliomas alters the enzyme's conformation and triggers pathways that lead to the disease. A Heidelberg group has developed a peptide vaccine that distinguishes mutant from normal enzyme and reduces tumor size in mice.1 The team is hoping the vaccine could join the race for a glioma immunotherapy but needs to show that it can generate enough neo-antigen-specific T cells and antibodies to spark an effective immune response in patients.

The group is preparing an IND and planning to start recruiting patients with glioma in 2Q15 for Phase I testing to assess the peptide's safety and immunogenicity...